Protalix BioTherapeutics (PLX) Cash from Investing Activities Growth (5y) (2015 - 2026)
Protalix BioTherapeutics (PLX) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Protalix BioTherapeutics | 192.04 Mn | 181.24 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.41% |
| Dec 31, 2025 | -16.51% |
| Sep 30, 2025 | -15.60% |
| Jun 30, 2025 | -10.32% |
| Mar 31, 2025 | 61.11% |
| Dec 31, 2024 | -250.67% |
| Sep 30, 2024 | 116.51% |
| Jun 30, 2024 | -13.63% |
| Mar 31, 2024 | -10.31% |
| Dec 31, 2023 | -43.44% |
| Sep 30, 2023 | -146.81% |
| Jun 30, 2023 | -13.28% |
| Mar 31, 2023 | 75.03% |
| Dec 31, 2022 | 171.56% |
| Sep 30, 2022 | 121.21% |
| Jun 30, 2022 | 20.31% |
| Mar 31, 2022 | -124.83% |
| Dec 31, 2021 | 174.80% |
| Sep 30, 2021 | 135.30% |
| Jun 30, 2021 | 86.56% |